Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,999 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,295,854.56. This trade represents a 39.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Down 2.6%

NASDAQ ORKA opened at $84.56 on Tuesday. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of -43.59 and a beta of -0.35. Oruka Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $97.78. The stock has a fifty day simple moving average of $70.87 and a 200 day simple moving average of $51.87.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. Research analysts expect that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 23rd. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings downgraded shares of Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Barclays upped their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Finally, Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.30.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB bought a new stake in Oruka Therapeutics in the second quarter worth approximately $15,313,000. Gradient Investments LLC bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $273,000. Avidity Partners Management LP boosted its holdings in shares of Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares in the last quarter. Glenmede Trust Co. NA grew its position in shares of Oruka Therapeutics by 11.7% during the 1st quarter. Glenmede Trust Co. NA now owns 21,772 shares of the company’s stock worth $1,068,000 after buying an additional 2,287 shares during the period. Finally, Remedium Capital Partners LLC grew its position in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after buying an additional 13,247 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.